What's New

To access our newest articles, webinars, and podcasts, click on the item of interest to view or download.

Articles

Lifecycle Management for Injectable Brands: Timing is Everything

Baxter’s Kristie Zinselmeier, Director of Marketing, discusses effective positioning of a molecule through Lifecycle Management (LCM) strategies

PM360 – Kristie Zinselmeier, Director of Marketing, June, 2010

Q&A with Brik Eyre

Life Science Leader interviews Baxter’s Brik Eyre, GM of their BioPharma Solutions business, on the future of the outsourcing market and how CMO partnerships may evolve

Life Science Leader – Brik Eyre, GM, January, 2010

Sizing Up CMOs

In their December '09 article in Life Science Leader, Wendy Turner, Director of Technical Programs, and Ninette Van Lingen, Pharma Partner Executive, help define the elements and expectations of successful outsourcing partnerships

Life Science Leader – Wendy Turner, Director of Technical Programs, and Ninette Van Lingen, Pharma Partner Executive; December, 2009

Ensure Safety, Efficacy of Ready-to-Use IV Drug Products

In their October/November '09 article in PFQ (2nd in a 3-part series), Baxter scientists Paula Youngberg Webb and Rao Chilamkurti discuss key stability considerations in the development of ready-to-use products.

Pharmaceutical Formulation & Quality – Paula Youngberg Webb, MS and Rao Chilamkurti, PHD, October/November 2009

The Future of Global Outsourcing

Baxter’s Sven Remmerbach, along with 7 other key industry players, talks about global outsourcing’s future in the November 2009 issue of Inside Outsourcing Learn more.

The Keys to RTU Parenterals

In their September '09 article in PFQ (1st in a 3-part series), Baxter scientists Rao Chilamkurti and Paula Youngberg Webb discuss the challenges related to formulation development of ready-to-use products.

Pharmaceutical Formulation & Quality – Paula Youngberg Webb and Rao Chilamkurti, September 2009

Moving From Vials to Prefilled Syringes: A Project Manager's Perspective

Baxter's Raul Soikes discusses the complex issues involved in switching an injectable therapeutic's presentation from a liquid or lyophilized vial to a prefilled syringe and describes a potential regulatory strategy for getting the newly formatted drug to market.

Pharmaceutical Technology Supplement – Raul Soikes, September 2009

Webinars

Shoot for Share: From Vial to Pre-Filled Syringe

According to recent estimates, the market for pre-filled systems is expected to top 2.4 billion by 2010. The increased interest in pre-filled syringes is in large part driven by the many advantages they offer to vials, including ease of use, reduced waste, improved dosing accuracy, and product differentiation.

Moving your drug from a vial to a pre-filled syringe offers market, customer, and product advantages. This complimentary webinar from Baxter BioPharma Solutions provides insight on: